(GSK) is making another bolt-on acquisition to strengthen its lineup, agreeing to pay an initial...

|By:, SA News Editor

(GSK) is making another bolt-on acquisition to strengthen its lineup, agreeing to pay an initial £146M ($227M) to acquire eczema drug Toctino from Swiss biotech Basilea (BPMUF.PK). GSK will pay another £50M if Toctino passes its Phase III trial and receives FDA approval, and royalties on U.S. sales starting three years after launch.